A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors AbbVie; Boehringer Ingelheim
- 06 Sep 2017 Status changed from active, no longer recruiting to completed.
- 25 Aug 2017 Trial has been completed in Czech Republic.
- 05 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.